CRMD Stock Summary and Trading Ideas (Cormedix | NASDAQ:CRMD)

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

Cormedix trades on the NASDAQ stock market under the symbol CRMD.

As of December 31, 2025, CRMD stock price declined to $11.63 with 3,436,891 million shares trading.

CRMD has a beta of 1.29, meaning it tends to be more sensitive to market movements. CRMD has a correlation of 0.07 to the broad based SPY ETF.

CRMD has a market cap of $916.32 million. This is considered a Small Cap stock.

Last quarter Cormedix reported $104 million in Revenue and $.57 earnings per share. This beat revenue expectation by $18 million and met earnings estimates .

In the last 3 years, CRMD traded as high as $17.43 and as low as $2.57.

The top ETF exchange traded funds that CRMD belongs to (by Net Assets): IWM, VTI, IWO, VXF, SCHA.

CRMD has outperformed the market in the last year with a price return of +43.6% while the SPY ETF gained +17.2%. However, in the short term, CRMD had mixed performance relative to the market. It has underperformed in the last 3 months, returning 0.0% vs +2.7% return in SPY. But in the last 2 weeks, CRMD shares have fared better than the market returning +1.7% compared to SPY +0.7%.

CRMD support price is $12.10 and resistance is $12.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRMD shares will trade within this expected range on the day.